Infections caused by Gram-negative bacteria (GNB) are increasingly common and can result in significant mortality rates due to the development of sepsis. To examine the potential usage of a recombinant Ad5-BPI 23 -Fcc1 virus as a biological treatment against systemic infection by GNB, a construct containing the human bactericidal/permeability increasing protein (BPI) gene, encoding the functional N terminus (amino acid residues 1-199) of human BPI, and the Fcc1 gene, encoding the Fc segment of human immunoglobulin G1, was inserted into an adenovirus serotype 5 (Ad5) chromosome to produce a recombinant Ad5-BPI 23 -Fcc1 virus. Human A549 cells in culture and BALB/c mice were infected with the recombinant Ad5-BPI 23 -Fcc1 virus and BPI 23 -Fcc1 expression was confirmed by Western blot analysis and ELISA. The concentrations of BPI 23 -Fcc1 protein were 5.59 mg ml "1 in vitro and 21.37 ng ml "1 in vivo and it was observed that these concentrations were sufficient to decrease endotoxin concentrations while enhancing bactericidal activity. In addition, mice treated with the recombinant Ad5-BPI 23 -Fcc1 virus had decreased levels of IL-1b and TNF-a and were protected from an E. coli O111 : B4 challenge. Our data support the concept that Ad5-mediated BPI 23 -Fcc1 gene delivery could be used as an ancillary biological treatment in the management of infection caused by GNB.
INTRODUCTION
Infections caused by Gram-negative bacteria (GNB) are increasingly common and significant mortality rates occur with the development of sepsis and septic shock. The increase in infections caused by GNB in patients is largely due to anti-cancer chemotherapy, immunosuppressive medicine after organ transplantation and invasive surgical procedures (Balk, 2000; Lazaron & Barke, 1999; Martin et al., 2003) . The high mortality rates associated with severe infection caused by GNB would be significantly decreased if efficient therapeutic reagents were clinically available that could enhance the effect of antimicrobials.
Bactericidal/permeability-increasing protein (BPI) is a 55 kDa cationic bactericidal protein expressed in human and other (bovine, porcine) mammalian polymorphonuclear neutrophil leukocytes. BPI can neutralize endotoxins and kill GNB directly; it also has no side effects on eukaryotic cells (Gray et al., 1989; Weiss & Olsson, 1987; Weiss et al., 1978) . The phase II/III trials of recombinant human BPIs (rBPI) rBPI 23 and rBPI 21 demonstrated that the administration of rBPI to children with meningococcaemia was tolerated and decreased morbidity but its effect on mortality rates was not investigated, likely due to the study being underpowered (Giroir et al., 1997; . rBPI 55 and rBPI 21 both had a short half-life of ,45 min in vivo and the treatment was very expensive (Elsbach & Weiss, 1998; Beamer, 2002) , making therapy with rBPI 21 less than ideal. In order to improve the activity and prolong the half-life of rBPI, we designed and expressed a recombinant human BPI 23 -Fcc1 fusion protein. We showed that BPI 23 -Fcc1 fusion protein had a prolonged half-life in vivo; it was also able to neutralize endotoxin, serve as an opsonin, directly kill GNB, including some drug-resistant GNB, and protect the host from lethal challenge with E. coli Xuefang et al., 2002) .
Subsequent studies demonstrated the protective efficacy of chimeric BPI 23 -Fcc1 gene delivery mediated by adenoassociated virus serotype 2 (AAV2) against lethal infection by GNB in mice. By the second week after BPI 23 -Fcc1 gene delivery by AAV2, the BPI 23 -Fcc1 protein was detectable in mouse serum. After the minimum lethal dose (MLD) of E. coli O111 : B4 or LPS challenge, the survival rate of AAV2-BPI 23 -Fcc1-gene-transferred mice was significantly higher than that of control mice (Chen et al., 2007; Li et al., 2006) . These results further supported evidence that AAV2-mediated BPI 23 -Fcc1 gene delivery had the potential for preventing or treating clinical high-risk patients from being infected by GNB (Chen et al., 2007) . Since AAV2-mediated target gene delivery showed low but long-term gene expression, which reached the peak at the second or third week post gene delivery, it could be suitable for preventing infection by GNB in high-risk patients or perhaps for use in combination with antimicrobials to treat serious infection by GNB.
Adenovirus serotype 5 (Ad5) is a common vector used clinically for gene therapy. Its main advantages are high efficiency of infection and easy production of high titres. The therapeutic effect of Ad5-mediated human BPI gene transfer in endotoxic mouse models has been established (Alexander et al., 2004) , while its efficacy in models of Gram-negative bacterial sepsis remains to be determined.
The goal of this study was to assess the efficacy of Ad5 as a vector for BPI 23 -Fcc1 gene delivery and investigate the underlying mechanisms. We studied the expression of BPI 23 -Fcc1 and how this expression affected endotoxin levels, bactericidal activity and IL-1b and TNF-a levels. In addition, the effect of pre-treating mice with the Ad5-BPI 23 -Fcc1 virus 3 days before challenge with an MLD of E. coli was also evaluated. Our results collectively supported the application of Ad5-BPI 23 -Fcc1 virus for the prevention of infection by GNB in high-risk patients.
METHODS
Bacterial strains and growth. E. coli DH5a (cat. no. CB101, Tiangen Biotech) and E. coli O111 : B4 (cat. no. 44101-9, China Medical Culture Collection) were grown in LB media Construction and production of Ad5-BPI 23 -Fcc1 virus. The BPI gene fragment encoding the signal peptide and the functional N terminus (1-199 amino acid residue) of human BPI, known as BPI 23 , was generated from the mRNA of the human HL-60 cell line (ATCC CCL-240) by RT-PCR using the primers P1 : 59-CTGGTACC-ATGAGAGAGAACATGGCCA-39 and P2 : 59-GCAAGCTTCTAT-TTTGGTCATTACTGGCAG-39. The Fcc1 gene fragment encoding the Fc fragment of human immunoglobulin G1 was generated from the mRNA of human peripheral blood lymphocytes derived from a healthy volunteer by RT-PCR using the primers P3 : 59-GTA-AGCTTCTACATGCCCACCGTGCCCAG-39 and P4 : 5'-TCGTCGA-CGGATCCTTATTTACCCGGAGACAGGGAG-39. BPI 23 and Fcc1 DNA fragments were digested with KpnI/HindIII and HindIII/SalI, respectively, and were then co-ligated into the KpnI/SalI sites of the pDC316 plasmid (AGTC Gene Technology), designed as the pDC316-BPI 23 -Fcc1 expression plasmid, in which the chimeric BPI 23 -Fcc1 gene controlled by the murine cytomegalovirus (MCMV) promoter and SV40 polyA was flanked by Ad5 inverted terminal repeats. Serum was collected by retro-orbital bleeding on the fifth day postinfection from mice treated with either Ad5-BPI 23 -Fcc1 virus (5610 8 IU) or the Ad5-Null virus (5610 8 IU). Immunoglobulin from the serum was precipitated using saturated ammonium sulfate, and the BPI 23 -Fcc1 protein in the immunoglobulin fraction was detected by Western blot analysis.
ELISA. An m.o.i. of 10 IU per cell was selected for Ad5-BPI 23 -Fcc1 virus treatment. A549 cells infected with the Ad5-BPI 23 -Fcc1 virus or Ad5-Null virus were incubated in DMEM medium containing 1 % FBS for 2, 3 or 4 days. The cell culture supernatants were then collected to measure the concentration of the human Fcc1 protein by using a human serum IgG ELISA kit (Alpha Diagnostic). The concentration of the BPI 23 -Fcc1 protein (mg ml 21 ) was calculated by the detected value (mg ml 21 ) multiplied by 96 kDa (the molecular mass of human BPI 23 -Fcc1) divided by 140 kDa (the molecular mass of human IgG1).
Serum was collected by retro-orbital bleeding on the third and fifth day after the mice were treated with either the Ad5-BPI 23 Concentrations of IL-1b and TNF-a in serum samples were detected by ELISA according to the manufacturer's instructions (R&D Systems).
Bactericidal assay. Human A549 cells were infected with the Ad5-BPI 23 -Fcc1 virus (10 IU per cell) or Ad5-Null virus (10 IU per cell) for 2 h at 37 uC, after which the viruses were removed and the cells were incubated with DMEM medium containing 1 % heat-inactivated FBS for 24 h. The infected cells were washed three times with PBS to remove excess viruses and then reincubated with fresh DMEM medium containing 1 % heat-inactivated FBS for 4 days. The cell culture supernatants were collected and 100 ml was mixed with 100 ml GNB (2.5610 4 c.f.u. ml 21 E. coli DH5a or E. coli O111 : B4) for 30 min. Bacterial titres were measured by serial 10-fold dilutions to evaluate the bactericidal activity of the BPI 23 -Fcc1 protein in vitro.
The MLD of E. coli O111 : B4 that caused a BALB/c mouse mortality rate of 90-100 % within 72 h was 2.5610 4 c.f.u. in sterile 0.5 ml 16 PBS containing 5 % (w/v) dried yeast (Chen et al., 2007) . BALB/c mice infected with either the Ad5-BPI 23 -Fcc1 virus or the Ad5-Null virus, as described earlier, were challenged via IP injection with the MLD of live E. coli O111 : B4. Survival was measured in three groups of mice; 45 mice were treated with the Ad5-BPI 23 -Fcc1 virus followed by bacterial challenge with O111 : B4, 35 mice were treated with the Ad5-Null virus followed by bacterial challenge with O111 : B4, and another 30 mice were treated with 16 PBS followed by bacterial challenge with O111 : B4. Survival rates were measured within 72 h.
Endotoxin neutralization assay. The ability of supernatants from A549 cells infected with the Ad5-BPI 23 -Fcc1 virus (10 IU per cell) or Ad5-Null virus to neutralize endotoxin was determined as previously reported (Obayashi et al., 1982) . In brief, 75 ml cell culture supernatant and 75 ml NaOH solution (0.18 M) were mixed in a sterile tube and incubated at 37 uC for 6 min. HClO 4 solution (75 ml, 0.32 M) was added followed by incubation at 37 uC for 12 min. NaOH solution (150 ml, 0.18 M) was then added and 50 ml of the solution was transferred into a new tube followed by the addition of 50 ml Tris/HCl/Mg 2+ solution (Mg 2+ 0.4 M, 0.01 M Tris/HCl; pH 8.0) and incubation at 37 uC for 30 min. Lastly, 50 ml of the pretreated cell culture supernatant generated as described earlier was mixed with 50 ml LPS [0.5 endotoxin units (EU) ml 21 ] and incubated at 37 uC for an additional 30 min. LPS concentrations were determined according to the instruction of the Limulus Amebocyte Lysate kit (Shyihua Corp.).
Serum samples from mice were diluted with endotoxin-free water and then assayed for the concentration of endotoxin according to the instructions of the Limulus Amebocyte Lysate kit.
Statistical analysis. Data are presented as mean±SD. A x 2 test was performed for the survival rate comparison. The difference between two groups was analysed by an independent-samples t-test (a50.05, two-sided). P-values ,0.05 were considered to be statistically significant. and 5.59±0.568 mg ml 21 , respectively (Fig. 1a) , while the BPI 23 -Fcc1 protein was not detected in the supernatants of A549 cells transfected with the Ad5-Null virus.
RESULTS

Expression of BPI
Western blot analysis was also performed on 10-foldconcentrated supernatants of A549 cells transfected with Ad5-BPI 23 -Fcc1 virus or Ad5-Null virus for 4 days. As shown in Fig. 1b , the expected 48 kDa band in DTT-deoxidized 
Biological activities of BPI 23 -Fcc1 protein in vitro
To assess whether BPI 23 -Fcc1 protein secreted from A549 cells transfected with the Ad5-BPI 23 -Fcc1 virus mediated bactericidal activity, culture supernatants at 4 days posttransfection were collected, 100 ml of cell culture supernatant and 100 ml E. coli DH5a or E. coli O111 : B4 (2.5610 4 c.f.u. ml
21
) were mixed together and incubated at 37 u C for 30 min, and bacterial c.f.u. were enumerated (Fig. 2) . The mean±SD c.f.u. of E. coli DH5a and O111 : B4 were less (116±35 c.f.u. ml 21 and 1764±6 c.f.u. ml
, respectively) when they were exposed to supernatants containing BPI 23 -Fcc1 protein compared to when they were exposed to supernatants where BPI 23 -Fcc1 protein was absent (2050±50 c.f.u. ml 21 and 2427±105 c.f.u. ml 21 , respectively). Statistically significant differences, P,0.001 (n53) for E. coli DH5a and P,0.001 (n53) for E. coli O111 : B4, were found between the activity of supernatants with or without BPI 23 -Fcc1 expression. These data show that secreted BPI 23 -Fcc1 protein has bactericidal activity.
To assess whether the secreted BPI 23 -Fcc1 protein could neutralize endotoxin, 50 ml cell culture supernatants were mixed with 50 ml endotoxin solution (0.5 EU ml 21 ) for 30 min at 37 u C. Limulus amoebocyte lysate (LAL) assays were then performed. The OD 545 value, which reflects the concentration of endotoxin, was significantly lower in mixtures containing BPI 23 -Fcc1 protein compared to mixtures that did not (0.785±0.081 versus 1.780±0.017; P,0.001, n53) ( Table 1 ). These data showed that secreted BPI 23 -Fcc1 protein was capable of neutralizing endotoxin.
BPI 23 -Fcc1 expression in vivo
To determine if the Ad5-BPI 23 -Fcc1 virus enabled BPI 23 -Fcc1 protein expression in vivo, IP injections of either Ad5-BPI 23 -Fcc1 virus or Ad5-Null virus were performed on mice. Serum samples were collected on the third and fifth days after treatment and processed as described earlier. On the fifth day post-treatment, a Western blot confirmed the presence of BPI 23 -Fcc1 protein in the sera from Ad5-BPI 23 -Fcc1-virus-treated mice by an expected 96 kDa band; no BPI 23 -Fcc1 protein was detected in sera from Ad5-Nullvirus-treated mice (Fig. 3a) . Sera were also examined by ELISA. The concentration of BPI 23 -Fcc1 protein in sera from mice treated with the Ad5-BPI 23 -Fcc1 virus was 21.37± 0.20 ng ml 21 (n54) on the third day and 30.53±9.04 ng ml 21 (n53) on the fifth day post-treatment. In contrast, BPI 23 -Fcc1 protein was not detected in the sera from mice treated with Ad5-Null control virus (Fig. 3b) . These results demonstrated that the Ad5 virus was efficient in its delivery and expression of the BPI 23 -Fcc1 gene in vivo. ) at 37 6C for 30 min followed by c.f.u. enumeration. *Statistically significant difference in the bacterial c.f.u. between the two groups (n53, P,0.001). 
Protection of mice from E. coli infection by Ad5-BPI 23 -Fcc1
The protective effect of Ad5-BPI 23 -Fcc1 virus against E. coli in mice
To determine whether treatment with the Ad5-BPI 23 -Fcc1 virus was able to protect mice against E. coli infection, BALB/c mice were challenged by IP injection with the MLD of E. coli O111 : B4 (2.5610 4 c.f.u. in 0.5 ml per mice) 3 days after treatment with Ad5-BPI 23 -Fcc1 virus (5610 8 IU in 100 ml; n545), Ad5-Null virus (5610 8 IU in 100 ml; n535) or PBS (100 ml; n530). The experimental end-point was survival within 72 h. At 12, 24, 36, 48, 60 and 72 h after bacterial challenge, survival rates were 91, 62, 53, 40, 83, 43, 14, 6, 6 and 6 % for Ad5-Null-virus-treated mice; and 83, 30, 10, 3, 3 and 3 % for PBS-treated mice (Fig. 4) . At 48, 60, and 72 h post-treatment, the survival rate of Ad5-BPI 23 -Fcc1-virus-treated mice (40 %) was significantly higher than that of Ad5-Null-virus-treated mice (5.71) (x 2 510.417, P,0.001) and PBS-treated control mice (3 %) (x 2 59.673, P,0.001). There was no statistically significant difference between the survival rates of the Ad5-Null-gene-transferred control mice and the PBS-treated control mice, further supporting evidence that the protective effect of the Ad5-BPI 23 -Fcc1 virus was due to BPI 23 -Fcc1 protein expression and not just due to virus infection. These results demonstrated that Ad5-mediated BPI 23 -Fcc1 treatment protected mice from lethal E. coli O111 : B4 infection.
Other biological effects of the BPI 23 -Fcc1 protein in vivo
To further evaluate biological effects of the BPI 23 -Fcc1 protein in Ad5-BPI 23 -Fcc-virus-treated mice, bacterial titres, endotoxin concentrations and the cytokines IL-1b and TNF-a were measured in the blood and tissues of E. coli-challenged mice. Aliquots of blood were obtained from the retro-orbital plexus and the liver and spleen were harvested at 3, 6, 9, 12 or 24 h after challenge with E. coli O111 : B4.
The bacterial titre was markedly less in the serum, homogenized spleen and liver of Ad5-BPI 23 -Fcc1-virustreated mice compared to Ad5-Null-virus-treated mice (Fig. 5a-c) . Differences were statistically significant in serum (n53, P50.003), spleen (n53, P50.021) and liver (n53, P50.015) samples at 12 h post-treatment. These results supported the concept that the expression of BPI 23 -Fcc1 protein enhanced host-mediated bactericidal activity.
Likewise, the endotoxin concentration was lower in the serum of Ad5-BPI 23 -Fcc1-virus-treated mice compared to Ad5-Null-virus-treated mice and these differences were statistically significant at 12 h (n53, P50.015) and18 h (n53, P50.003) (Fig. 6a) .
We observed that the levels of IL-1b peaked at 12 h and TNF-a peaked at 18 h in the serum of Ad5-BPI 23 -Fcc1-virus-treated mice. The level of IL-1b at 12 h (n53, P50.047) and the level of TNF-a at 18 h (n53, P50.006) were also significantly lower than that of Ad5-Null-virustreated mice after the lethal E. coli infection (Fig. 6b, c) .
Together, our results demonstrated that mice treated with the Ad5-BPI 23 -Fcc1 virus showed decreased mortality rates compared to Ad5-Null-virus-treated mice, which was accompanied by enhanced bacterial clearance and decreased serum endotoxin and proinflammatory cytokine concentrations. Survival rate (%) Fig. 4 . Ad5-BPI 23 -Fcc1-mediated protection from lethal E. coli infection. At 12, 24, 36, 48, 60 and 72 h post-infection, the survival rate of Ad5-BPI 23 -Fcc1-virus-treated mice (n545) was higher than that of Ad5-Null-virus-treated mice (n535) and PBStreated mice (n530). P,0.001 for Ad5-BPI 23 -Fcc1-virus-treated compared with Ad5-Null-virus-and PBS-treated mice at 48, 60, and 72 h.
DISCUSSION
With the increasing incidence in antimicrobial resistance and a paucity of new antimicrobials in the pharmaceutical pipeline, continued investigation of antimicrobial peptides as anti-infection agents is urgent and justified. Potential advantages of antimicrobial peptides include their broadspectrum activities and the observation that pathogens do not appear to be able to develop resistance easily (Jenssen et al., 2006) . Potential limitations include high cost and a short half-life. One approach to overcome these limitations is the delivery of antimicrobial peptides by an adenovirus vector. There are more than 50 serotypes of human adenovirus, and genetically engineered derivatives of human serotype 5 adenoviruses are often selected as vectors for gene delivery due to their safety, as they are replication deficient in humans (Havenga et al., 2001) . It has been established that this vector can deliver and express target genes in liver, lung, muscle and fibroblast cells. Expression of the target gene begins 8 h after viral delivery and continues for up tõ 10-14 days (Tomanin & Scarpa, 2004) . Based on these data, the usage of genetically engineered recombinant Ad5 may serve as a viable method for the delivery of antimicrobial peptides.
In this study, we constructed an Ad5-BPI 23 -Fcc1 recombinant virus. After transfection of A549 cells, BPI 23 -Fcc1 protein was detected in the cell culture supernatant, which was sufficient to kill E. coli DH5a or inhibit the growth of E. coli O111 : B4 at this concentration. This bactericidal activity of Ad5-BPI 23 -Fcc1 virus against E. coli O111 : B4 is likely to be due to the presence of a complete O-antigen (Chart et al., 2000; Raetz, 1990; Raetz & Whitfield, 2002; Russo & Mylotte, 1998) . We also showed that the presence of BPI 23 -Fcc1 protein in supernatants of A549 cells enhanced endotoxin neutralization. Our results were consistent with a previous report in that when treated with Ad5-BPI recombinant virus, the survival rate of was up to 80 % for 1 day post-LPS-challenged mice. These results pointed to a possible beneficial effect of BPI in the treatment of infection caused by GNB. We further assessed the treatment of mice with the Ad5-BPI 23 -Fcc1 virus. After treatment of BALB/c mice with Ad5-BPI 23 -Fcc1 recombinant virus (5610 8 IU), BPI 23 -Fcc1 protein was detected in the serum at a concentration of 21.37 ng ml 21 on the third day and 30.53 ng ml 21 on the fifth day post-transfection.
To determine the effects of BPI 23 -Fcc1 protein at these concentrations on proinflammatory response, endotoxin neutralization and bacterial clearance, we examined mice challenged with E. coli infection. After challenge with an MLD of E. coli O111 : B4, the survival rate of mice treated with Ad5-BPI 23 -Fcc1 recombinant virus (40 %) was significantly higher than that of those treated with the Ad5-Null recombinant virus (5.71 %). Increased survival rate of Ad5-BPI 23 -Fcc1-treated mice was associated with significantly decreased E. coli titres and levels of endotoxin and proinflammatory cytokine in serum compared to Ad5-Null-treated mice (P,0.05). Survival rates were similar when Ad5-BPI 23 -Fcc1 treatment was administered intramuscularly (data not shown). Our results were consistent with findings of studies where AAV2-BPI 23 -Fcc1 recombinant virus has been used (Chen et al., 2007) .
Transgene expression can be detected within 18 h of infection and can reach maximal levels 48-72 h after infection (Wang et al., 1998) in an Ad5 animal model. The high efficiency of Ad5 vector-mediated anti-infection gene expression could be useful to treat acute infection by GNB.
In AAV animal models, target gene expression was at a moderate-high level and was maintained for 2 weeks; thus, it could be suitable for prevention of infection by GNB (Chen et al., 2007; Li et al., 2006) .
One of the disadvantages of the Ad5 vector is that most people have neutralizing antibodies to the Ad5 vector due to previous natural adenovirus infection, which could block the use of Ad5 vector. For example, approximately 40-69 % of healthy adults in America were found to be Ad5-seropositive by measuring the Ad5-neutralizing antibodies in blood samples (Nwanegbo et al., 2004) . Systemic administration of adenovirus vectors also led to a rapid innate immune response against the capsid, vector DNA genome and viral protein (Yamaguchi et al., 2007; Nayak & Herzog, 2010) , including induction of cytokines, inflammation, transient liver toxicity and thrombocytopenia. To avoid the neutralization of Ad5, or other immune responses, systemic administration could be replaced by local administration such as muscle injection, as muscle injection of Ad5 vector lowered the immune response. In addition, Ad5 vector could also be replaced by another serotype of adenovirus such as Ad4 or Ad30. In summary, our results further support the use of an adenovirus vector to deliver antimicrobial peptides as anti-bacterial agents. Given the concentration and duration of BPI expression, studies to assess its potential to prevent development of infection and sepsis in high-risk patients, such as cancer patients with impending neutropenia, bone marrow or solid organ transplant patients, or select surgical patients, in which faecal soilage of the peritoneum is highly anticipated.
